1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks

Friedreich Ataxia

1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks

gamma interferon

Open Trail of γIFN for Friedreich Ataxia

Safety and Efficacy of γIFN Treatment in Friedreich Ataxia

number of AE and SAE reported by treated patients along the study. Safety of γIFN treatment given for 6 months at final dose of 200 mcg three times weekly in FRDA patients

changes in scores at the SARA scale assessed at various time points (from 6 moths before treatment start to 6 months after treatment stop) for each patient

intensity of BOLD signal in FRDA patients performing the finger tapping protocol at least 6 months prior to treatment start, at treatmenet start, after 6 months of treatment and 6 months after treatment discontinuation

Mean Thickness of RNFL and thickness in the 4 quadrants as resulting from OCT exam

changes in ventricular and interventricular walls thickness (mm) at various time points for each patient

changes in Frataxin levels (intensity of frataxin band at western blot) associated with treatment

scores at SF36 assessed along time in each patient

Fractional anysotropy values at selected ROI as measured at various time points in each patient

changes in WHO-DAS 2.0 scores recorede along time

MD values at selected ROI as measured at various time points in each patient

Andrea Martinuzzi

Director of neurorehabilitation department

IRCCS Eugenio Medea

Clinical monitoring and best supportive care.

Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.

Cancer

Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.

Spironolactone (+/- Furosemide)

Centre Hospitalier Intercommunal Compiègne-Noyon

Polyclinique de Grande Synthe

CHRU Lille

Hôpital Saint Vincent de Paul

Centre Oscar Lambret

Institut Curie

Hôpital Jean Jaurès

GH Diaconesses Croix St Simon

Hôpital Lyon Sud

Institut Jean Godinot

Centre Eugène Marquis

Centre Paul Strauss

Centre Hospitalier Tourcoing

Polyclinique Vauban

Institut Gustave Roussy

Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

A Randomized Cross-over Trial Evaluating the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Palliative Stage of Cancer

Adverse events and serious adverse events related to diuretic treatment according to NCI-CTCAE v4.0

Growth pattern doses of diuretics, decrement pattern doses of diuretics, maintenance doses of diuretics, maximum doses reached of diuretics.

National Cancer Institute, France

Goal directed volume therapy is most often guided by stroke volume measurements by OD.

The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.

Postoperative Complications

Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.

Volume of colloid infusion

Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.

Anestesi-och operationskliniken

Non Invasive Methods to Guide Volume Optimization

Evaluation of Non Invasive Methods for Goal Directed Fluid Therapy During Abdominal Surgery

Volume colloid fluid to achieve volume optimisation for guidance using Pleth Variability Index and oesophageal doppler, respectively (comparison between groups)

Correlation between level of dehydration measured by volume kinetics and urinary analysis, and correlation between these two circumstantials and the volume of colloids given for the first volume optimisation using Pleth Variability Index or oesophageal doppler

papillon-lefevre disease/albumin

Open Trail of γIFN for Friedreich Ataxia

Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)

Non Invasive Methods to Guide Volume Optimization

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum